These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21419223)

  • 1. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension.
    Shao D; Park JE; Wort SJ
    Pharmacol Res; 2011 Jun; 63(6):504-11. PubMed ID: 21419223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.
    Davie NJ; Schermuly RT; Weissmann N; Grimminger F; Ghofrani HA
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():38-49. PubMed ID: 19335746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
    de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
    Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin.
    Van Hung T; Emoto N; Vignon-Zellweger N; Nakayama K; Yagi K; Suzuki Y; Hirata K
    Life Sci; 2014 Nov; 118(2):313-28. PubMed ID: 24412382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow.
    Petrossian E; Parry AJ; Reddy VM; Akkersdijk GP; McMullan DM; Thompson L; Hendricks-Munoz KD; Hallak H; Hanley FL; Fineman JR
    J Thorac Cardiovasc Surg; 1999 Feb; 117(2):314-23. PubMed ID: 9918974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
    Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin in cardiovascular control: the role of endothelin antagonists.
    Wenzel RR; Czyborra P; Lüscher T; Philipp T
    Curr Hypertens Rep; 1999; 1(1):79-87. PubMed ID: 10981046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1.
    McMullan DM; Bekker JM; Johengen MJ; Hendricks-Munoz K; Gerrets R; Black SM; Fineman JR
    Am J Physiol Heart Circ Physiol; 2001 Feb; 280(2):H777-85. PubMed ID: 11158977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative mediator role of endothelin-1 in asthma and other lung diseases.
    Hay DW
    Clin Exp Pharmacol Physiol; 1999 Feb; 26(2):168-71. PubMed ID: 10065341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
    Shiwen X; Leask A; Abraham DJ; Fonseca C
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endothelin system in pulmonary hypertension.
    Michel RP; Langleben D; Dupuis J
    Can J Physiol Pharmacol; 2003 Jun; 81(6):542-54. PubMed ID: 12839266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
    Neuhofer W; Gülberg V; Gerbes AL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.